What is Celcuity's other accrued license milestone?

Celcuity (CELC) reported other accrued license milestone of $5M in Q4 2025.

What does other accrued license milestone mean?

This represents the liability for contractual milestone payments owed to third-party licensors based on the achievement of specific development or regulatory goals. It highlights the company's future financial commitments tied to the successful progression of its clinical pipeline.

Celcuity CELC Other Accrued License Milestone

Other Accrued License Milestone at other companies

Catalyst PharmaceuticalCPRX

$3.13M—

Crinetics PharmaceuticalsCRNX

$1.5M—

Ionis PharmaceuticalsIONS

$6.66M-9.8%

Denali Therapeutics Inc.DNLI

$495M—

Lantheus HoldingsLNTH

$4.9B—

InsmedINSM

$15M—

Other financials

Income statement

See full

Operating income-$50.5M-39.8%

Net income-$52.8M-42.8%

EPS (diluted)-$0.97-12.8%

Balance sheet

See full

Cash & equivalents$145.2M+781%

Total debt$137.9M+30.7%

Total equity$53.5M-38.2%

Total assets$410.2M+88.0%

Cash flow

See full

Operating cash flow-$55.1M-53.6%

CapEx$249.0K+315%

Free cash flow-$55.3M-54.0%

Valuation

See full

Market cap$4.4B+1,370%

Returns & leverage

See full

Return on equity-275.2%-990pp

Debt / equity2.6×+1.4×

Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept CELC:OtherAccruedLicenseMilestone.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's other accrued license milestone.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Celcuity's other accrued license milestone?: Celcuity (CELC) reported other accrued license milestone of $5M in Q4 2025.
What does other accrued license milestone mean?: This represents the liability for contractual milestone payments owed to third-party licensors based on the achievement of specific development or regulatory goals. It highlights the company's future financial commitments tied to the successful progression of its clinical pipeline.